IMM2902 of ImmuneOnco Completed the First Patient Dosing

    February 15, 2022, Shanghai, China.  ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco", the company) announced that the first bispecific antibody-receptor recombinant protein (project number: IMM2902) targeting human CD47 x HER2 has completed the first patient enrollment and dosing, and administration process was smooth and successful.  

    IMM2902, a CD47xHER2 bispecific fusion protein designed for solid tumors, is at the forefront of global research. The project has previously been approved by the National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA) for clinical trials on June 29, 2021 and August 21, 2021. It is the third new drug project in the clinical research stage of the company based on targeting CD47/SIRPa. The completion of the first subject enrollment and dosing in the IMM2902 project is another major milestone for the company.

Dr. Wenzhi Tian, Founder and CEO of the company, is very confident in the clinical trial research of IMM2902.

    "We are very pleased that our IMM2902 project has completed the first patient in. IMM2902 is a bispecific molecule developed on our mAb-Trap technique platform for CD47 and HER2. The molecule preferentially binds to tumor cells through the high affinity to HER2 and CD47, at the same time, it doesn’t bind to human red blood cells and other off-target cells, so as to avoid the "Antigen sink” effect, thereby greatly enhance the synergistic effect based on both targets against tumors. IMM2902 will have great potential in clinical development and commercial value.”

About IMM2902

    IMM2902 is a new-generation bispecific drug candidate with global proprietary intellectual property rights, developed based on ImmuneOnco "mAb-Trap" technical platform. IMM2902 targets immune regulatory target CD47 and HER2, to inhibit tumor cell growth by accelerating the endocytosis and degradation of HER2, and to disinhibit and enhance the phagocytosis of macrophages against tumor cells by blocking the "don't eat me" signal mediated by CD47-SIRPα and activating the "eat me" signal mediated by Ig1Fc-FcγR. By the phagocytosis, processed tumor antigen was presented to T cells thereby exerting a powerful effect of tumor immunotherapy. IMM2902 is expected to be used mainly for HER2-expressing advanced solid tumors such as breast cancer, stomach cancer and lung cancer.

About ImmuneOnco

    Founded in June 2015 at Zhangjiang Hi-Tech Park of China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bi-specific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy. Our compounds aim to activate patients’ own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can return gradually to being healthy. Currently, several new anti-tumor products are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winners of the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.